Literature DB >> 9738663

Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells.

R L Paquette1, N C Hsu, S M Kiertscher, A N Park, L Tran, M D Roth, J A Glaspy.   

Abstract

The diverse roles of interferon-alpha (IFN-alpha) in regulating the immune response to infectious agents suggested that it might affect dendritic cell (DC) development. Peripheral blood mononuclear cells cultured with IFN-alpha and granulocyte-macrophage colony-stimulating factor (GM-CSF) developed a dendritic morphology and expressed high levels of the class I and II human leukocyte antigens (HLA), B7 co-stimulatory molecules, adhesion proteins, and CD40. Elevated DC expression of B7-2 and HLA-DR was observed with increasing IFN-alpha concentrations up to 5000 U/mL. The effects of IFN-alpha on DC immunophenotype were not reversed by adding neutralizing antibodies against interleukin-4 (IL-4) or tumor necrosis factor alpha to the cell cultures or by eliminating lymphocytes from the cultures. The addition of IFN-alpha to cultures containing optimal concentrations of IL-4 and GM-CSF significantly increased the B7-2 and HLA-DR levels above those present on DCs grown in two cytokines. The DCs generated with IFN-alpha and GM-CSF were potent antigen-presenting cells in allogeneic mixed leukocyte reactions. They also were capable of taking up, processing, and presenting tetanus toxin to autologous T lymphocytes. These results demonstrate an important role for IFN-alpha in the generation of DCs with potent antigen-presenting capabilities from peripheral blood monocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738663     DOI: 10.1002/jlb.64.3.358

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  66 in total

1.  Monocyte-derived dendritic cells: a potential target for therapy in multiple sclerosis (MS).

Authors:  M E Duddy; G Dickson; S A Hawkins; M A Armstrong
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

Review 2.  The specialized roles of immature and mature dendritic cells in antigen cross-presentation.

Authors:  Richard A Hopkins; John E Connolly
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

3.  Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.

Authors:  Jian-Hua Ma; Emilia Patrut; Jan Schmidt; Hanns-Peter Knaebel; Markus W Büchler; Angela Märten
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

Review 4.  Human dendritic cell subsets for vaccination.

Authors:  Peter Dubsky; Hideki Ueno; Bernard Piqueras; John Connolly; Jacques Banchereau; A Karolina Palucka
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

5.  Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity.

Authors:  A Tamir; W J Jordan; M Ritter; N Habib; R I Lechler; G R Foster; G Lombardi
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 6.  Regulation of antiviral T cell responses by type I interferons.

Authors:  Josh Crouse; Ulrich Kalinke; Annette Oxenius
Journal:  Nat Rev Immunol       Date:  2015-03-20       Impact factor: 53.106

7.  Type I IFN drives a distinctive dendritic cell maturation phenotype that allows continued class II MHC synthesis and antigen processing.

Authors:  Daimon P Simmons; Pamela A Wearsch; David H Canaday; Howard J Meyerson; Yi C Liu; Ying Wang; W Henry Boom; Clifford V Harding
Journal:  J Immunol       Date:  2012-02-27       Impact factor: 5.422

8.  Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant.

Authors:  M Paula Longhi; Christine Trumpfheller; Juliana Idoyaga; Marina Caskey; Ines Matos; Courtney Kluger; Andres M Salazar; Marco Colonna; Ralph M Steinman
Journal:  J Exp Med       Date:  2009-06-29       Impact factor: 14.307

9.  CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.

Authors:  Edmund A Rossi; David M Goldenberg; Thomas M Cardillo; Rhona Stein; Chien-Hsing Chang
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

Review 10.  Physiological role of plasmacytoid dendritic cells and their potential use in cancer immunity.

Authors:  Jorge Schettini; Pinku Mukherjee
Journal:  Clin Dev Immunol       Date:  2009-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.